ASP Isotopes (NASDAQ:ASPI) Stock Price Down 5.3% – What’s Next?

ASP Isotopes Inc. (NASDAQ:ASPI) shares dropped 5.3% during mid-day trading on Tuesday . The company traded as low as $3.73 and last traded at $3.8050. Approximately 694,779 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 4,787,871 shares. The stock had previously closed at $4.02.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Wall Street Zen upgraded shares of ASP Isotopes from a “strong sell” rating to a “sell” rating in a report on Saturday, August 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of ASP Isotopes in a research note on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, ASP Isotopes has an average rating of “Hold” and a consensus price target of $13.00.

ASP Isotopes Stock Performance

The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.85 and a current ratio of 3.87. The stock has a market capitalization of $602.50 million, a P/E ratio of -2.98 and a beta of 3.59. The business has a 50-day moving average price of $4.46 and a 200 day moving average price of $5.22.

ASP Isotopes (NASDAQ:ASPI) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.11). The company had revenue of $5.12 million for the quarter, compared to the consensus estimate of $4.47 million. ASP Isotopes had a negative net margin of 427.98% and a negative return on equity of 64.99%.

Insider Buying and Selling

In related news, COO Robert Ainscow sold 8,438 shares of the company’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $7.00, for a total value of $59,066.00. Following the transaction, the chief operating officer owned 2,281,879 shares in the company, valued at $15,973,153. The trade was a 0.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Todd Wider sold 50,000 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $6.25, for a total transaction of $312,500.00. Following the sale, the director directly owned 722,247 shares in the company, valued at $4,514,043.75. This trade represents a 6.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 111,562 shares of company stock valued at $704,885 over the last ninety days. Insiders own 14.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ASPI. Mercer Global Advisors Inc. ADV grew its holdings in shares of ASP Isotopes by 8.3% during the third quarter. Mercer Global Advisors Inc. ADV now owns 21,056 shares of the company’s stock valued at $203,000 after buying an additional 1,622 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in ASP Isotopes by 9.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,840 shares of the company’s stock worth $153,000 after acquiring an additional 1,878 shares during the last quarter. Legal & General Group Plc lifted its position in ASP Isotopes by 30.4% in the 3rd quarter. Legal & General Group Plc now owns 8,377 shares of the company’s stock valued at $81,000 after acquiring an additional 1,953 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in ASP Isotopes by 8.8% during the 1st quarter. The Manufacturers Life Insurance Company now owns 30,503 shares of the company’s stock valued at $135,000 after purchasing an additional 2,470 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in ASP Isotopes by 84.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock valued at $41,000 after purchasing an additional 2,548 shares during the last quarter. Institutional investors own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.